New Cannabis Derivative Offers ‘Holy Grail’ Outcome in the Treatment of MS
Emerald Health, a Canadian cannabis pharmaceutical company, is developing what could be a “holy grail” treatment for sufferers of Multiple Sclerosis (MS).
Emerald Health, a Canadian cannabis pharmaceutical company, is developing what could be a “holy grail” treatment for sufferers of Multiple Sclerosis (MS).
The cannabis community is increasingly recognizing the tremendous benefits gained by combining CBD with THC and other cannabis compounds in cannabis products. What’s less recognized than the entourage effect, but nonetheless gaining traction, is the importance of combining CBD with THC in fixed proportions, or ratios.